Guangdong-based Vision Medicals has reportedly secured hundreds of millions of renminbi in a Series D+ financing round, led by Kequan Investment with participation from Tianxin Fund. The funds raised will be directed towards accelerating the research and development of precision diagnosis products focused on pathogenic molecules. Additionally, the company plans to implement its integral solutions across top medical institutions nationwide and establish an advanced production base for molecular diagnostic reagents and instruments.
Founded in 2018, Vision Medicals has established a robust footprint in the medical diagnostics space. The company operates a research and development center, a medical laboratory, and a GMP production base for in vitro diagnostic products, spanning an area of over 10,000 square meters. With testing centers and branch offices in Beijing, Shanghai, Guangzhou, Zhengzhou, Chengdu, and other locations, Vision Medicals has accumulated a large dataset of pathogen metagenomics from more than 400,000 cases. The company has also played a role in the early detection and identification of major pathogens, including COVID-19.- Flcube.com
